Test New Page | GSK UK

Positively impacting society and the planet

Access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Company

Global health and health security

We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.

Global health and health security

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Diversity, equity and inclusion

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Ethical standards

B1e4411895528d3e028825e28a73340d695bdd09

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

Product governance

Label

Heading

£m (unless stated)	2023	2024	2025	2026	2027	2023-2027 n=	1	2	3
Turnover - Vaccines ex pandemic solutions	10,491	11,500	12,436	13,033	13,295	13,647	14,017	14,059	15
Turnover - Specialty ex pandemic solutions	11,446	12,455	13,484	14,472	14,542	14,511	13,844	12,903	15
Turnover - General Medicines	9,680	9,607	9,572	9,323	8,944	8,635	8,026	7,307	15
Turnover - GSK excluding pandemic solutions	31,616	33,561	35,492	36,828	36,781	36,793	35,887	34,269	15
Turnover - pandemic solutions	1	0	0	0	0	0	0	0	15
Turnover - GSK	31,617	33,561	35,492	36,828	36,781	36,793	35,887	34,269	15
Cost of sales	(7,839)	(8,211)	(8,595)	(8,872)	(8,969)	(9,092)	(8,999)	(8,631)	15
Selling, general and administration	(9,139)	(9,471)	(9,798)	(10,055)	(10,056)	(10,173)	(10,112)	(9,869)	15
Research and Development	(6,020)	(6,272)	(6,533)	(6,748)	(6,775)	(6,848)	(6,828)	(6,710)	15
Royalty income	571	594	643	627	527	513	517	467	15
Operating profit	9,189	10,201	11,209	11,780	11,508	11,195	10,466	9,527	15
Net finance costs	(594)	(536)	(508)	(461)	(402)	(359)	(310)	(256)	15
Associates	(2)	(2)	(2)	(2)	(2)	(2)	(2)	(3)	15
Profit before tax	8,593	9,664	10,700	11,317	11,104	10,834	10,154	9,269	15
Taxation	(1,458)	(1,659)	(1,846)	(1,961)	(1,925)	(1,868)	(1,753)	(1,594)	15
Tax Rate	17.0%	17.2%	17.2%	17.3%	17.3%	17.2%	17.3%	17.2%	15
Profit after tax	7,136	8,004	8,854	9,356	9,179	8,966	8,401	7,675	15
Minority interests	(636)	(672)	(703)	(726)	(666)	(595)	(493)	(361)	15
Profit attributable to shareholders	6,499	7,332	8,152	8,630	8,513	8,371	7,909	7,314	15
WANS (m)	4,070	4,088	4,104	4,115	4,117	4,112	4,110	4,107	15
Earnings per share (p)	159.7	179.4	198.6	209.7	206.7	203.5	192.7	179.1	15
Dividend per share (p)	60.0	62.1	64.3	66.1	68.0	69.0	69.3	69.1	14
Free Cash Flow	4,953	6,097	6,919	7,293	7,180	7,244	7,097	6,826	12
Net Debt	(12,020)	(8,742)	(4,756)	(640)	3,185	7,356	11,105	15,838	12

USD / GBP	1.26	1.26	1.26	1.26	1.26	1.26	1.26	1.26	15
EUR / GBP	1.17	1.17	1.17	1.17	1.17	1.17	1.17	1.17	14
JPY / GBP	191	193	193	193	193	193	193	193	11

Turnover £m	2023	2024	2025	2026	2027	2023-2027 n=
Shingrix	3,929	4,435	4,862	4,974	5,002	5,060	5,033	4,908	15
Arexvy	1,543	1,956	2,341	2,639	2,638	2,685	2,804	2,726	15
Bexsero	880	900	909	914	920	911	917	902	15
Menveo	402	406	408	408	410	405	407	392	15
Other Meningitis	29	29	29	29	29	29	29	27	9
Meningitis	1,311	1,335	1,346	1,351	1,359	1,345	1,353	1,321	15
Fluarix/Flulaval	468	458	451	446	441	437	434	424	15
Boostrix	614	621	627	633	639	639	645	642	15
Cervarix	117	116	116	115	114	112	111	116	14
Hepatitis	632	652	665	675	686	691	701	697	15
Infanrix, Pediarix	522	518	515	514	513	513	513	508	15
Priorix	284	285	286	287	287	288	288	264	9
Rotarix	616	627	633	640	646	651	657	654	15
Synflorix	243	227	216	209	203	198	194	180	15
Established Vaccines	3,233	3,246	3,251	3,264	3,279	3,276	3,293	3,260	15
Other Vaccines pipeline	7	69	185	360	576	844	1,100	1,420	15
Vaccines ex pandemic solutions	10,491	11,500	12,436	13,033	13,295	13,647	14,017	14,059	15
Pandemic solutions	-	-	-	-	-	-	-	-	15
Vaccines	10,491	11,500	12,436	13,033	13,295	13,647	14,017	14,059	15

testing